参考文献
［1］Litwin MS，Tan HJ.The diagnosis and treatment of prostate cancer：a review［J］.JAMA，2017，317（24）：2532-2542.
［2］Ma B，Wells A，Wei L，et al. Prostate cancer liver metastasis：Dormancy and resistance to therapy［J］.semin cancer biol，2020，71：2-9.
［3］Siegel RL，Miller KD，Jemal A.Cancer statistics，2020［J］.CA：a cancer journal for clinicians，2020，70（1）：7-30.
［4］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA：A Cancer Journal for Clinicians，2016，66（2）：115-132.
［5］Committee CAAG. Chinese experts consensus on the treatment of metastatic prostate cancer 2018［J］.Chinese journal of surgery，2018，56（9）：11.
［6］Gandaglia G，Abdollah F，Schiffmann J，et al. Distribution of metastatic sites in patients with prostate cancer：A population-based analysis［J］.The Prostate，2014，74（2）：210-216.
［7］Taneja SS.Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer［J］.The Journal of Urology，2016，196（3）：742.
［8］Pond GR，Sonpavde G，de Wit R，et al.The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer［J］.Eur Urol，2014，65（1）：3-6.
［9］Iczkowski KA，Lucia MS.Current perspectives on Gleason grading of prostate cancer［J］.Curr Urol Rep，2011，12（3）：216-222.
［10］Sweeney CJ，Chen YH，Carducci M，et al.Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer［J］.N Engl J Med，2015，373（8）：737-746.(https://www.daowen.com)
［11］James ND，Sydes MR，Clarke NW，et al.Addition of docetaxel，zoledronic acid，or both to first-line long-term hormone therapy in prostate cancer（STAMPEDE）：survival results from an adaptive，multiarm，multistage，platform randomised controlled trial［J］.Lancet，2016，387（10024）：1163-1177.
［12］Fitzpatrick JM，de Wit R.Taxane mechanisms of action：potential implications for treatment sequencing in metastatic castration-resistant prostate cancer［J］.Eur Urol，2014，65（6）：1198-1204.
［13］Vale CL，Burdett S，Rydzewska LHM，et al.Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic，hormone-sensitive prostate cancer：a systematic review and metaanalyses of aggregate data［J］.The Lancet Oncology，2016，17（2）：243-256.
［14］Potter GA，Barrie SE，Jarman M，et al.Novel steroidal inhibitors of human cytochrome P45017 alpha（17 alpha-hydroxylase-C17，20-lyase）：potential agents for the treatment of prostatic cancer［J］.J Med Chem，1995，38（13）：2463-2471.
［15］Taneja SS. Abiraterone plus prednisone in metastatic，castrationsensitive prostate cancer［J］.The Journal of Urology，2018，199（1）：26-28.
［16］Faiena I，Salmasi A，Pantuck AJ，et al.Abiraterone for prostate cancer not previously treated with hormone therapy［J］.Eur Urol，2018，73（6）：981.
［17］Rusthoven C G，Jones B L，Flaig T W，et al.Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer［J］.J Clin Oncol，2016，34（24）：2835-2842.
［18］Tabata K，Satoh T，Tsumura H，et al.PD28-08 radiotherapy for prostate in men with metastatic prostate cancer：a propensity-scope matching analysis［J］.Journal of Urology，2016，195（4）：e657.
［19］Freedland SJ，Howard LE，Hanyok BT，et al.Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer［J］.Bju Int，2016，118（4）：570-577.
［20］Taneja SS.Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer［J］.The Journal of Urology，2016，196（3）：742.